MCAS-POTS Overlap Syndrome

Condition: MCAS-POTS Overlap Syndrome  |  Category: Inflammation and Immune Health  |  Reviewed by: Brian Lamkin, DO

What Is MCAS-POTS Overlap?

MCAS-POTS overlap is the clinical coexistence of mast cell activation syndrome and postural orthostatic tachycardia syndrome in which the two conditions share common triggers, amplify each other's pathophysiology, and produce a combined symptom burden that exceeds what either condition produces alone. This is not a rare coincidence. Research increasingly demonstrates that mast cell activation is present in a substantial subset of POTS patients, and conversely, autonomic dysfunction is frequently identified in patients with established MCAS.

The mechanistic connection is bidirectional. Mast cell degranulation releases histamine, prostaglandins, leukotrienes, and other vasoactive mediators that produce peripheral vasodilation, directly reducing venous return and worsening the orthostatic tachycardia that defines POTS. Simultaneously, the autonomic nervous system normally provides inhibitory regulation of mast cell degranulation through sympathetic and parasympathetic pathways, and when autonomic function is impaired (as in POTS), this regulatory brake is weakened, allowing mast cells to degranulate more easily and more frequently.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

The overlap between MCAS and POTS is not coincidental. These conditions share common upstream drivers that predispose to both autonomic dysfunction and mast cell instability.

Post-Infectious Immune Dysregulation

Viral infection (particularly COVID-19, Epstein-Barr, and other herpesviruses) can trigger both autoimmune autonomic neuropathy and mast cell activation simultaneously. The immune dysregulation that follows infection disrupts both the neural pathways governing cardiovascular autonomic function and the regulatory mechanisms that keep mast cells quiescent. Long COVID is now a primary risk factor for new-onset MCAS-POTS overlap.

Connective Tissue Laxity (Ehlers-Danlos Spectrum)

Hypermobile EDS and hypermobility spectrum disorders produce excessive venous pooling from vascular laxity (contributing to POTS) and may alter the extracellular matrix environment in which mast cells reside (contributing to MCAS instability). The triad of MCAS, POTS, and EDS is one of the most clinically significant and most frequently unrecognized patterns in complex chronic illness.

Autoimmune Mechanisms

Autoantibodies directed against autonomic receptors (adrenergic, muscarinic) have been identified in POTS patients. Similar autoimmune mechanisms targeting IgE receptor pathways and mast cell regulatory systems may contribute to MCAS instability. Systemic inflammation measured by elevated hs-CRP and other inflammatory markers compounds both pathways.

HPA Axis Dysregulation

Cortisol plays a stabilizing role in mast cell regulation, and HPA axis dysfunction that produces flat or insufficient cortisol response allows mast cell degranulation thresholds to lower. The same cortisol dysregulation impairs autonomic cardiovascular regulation. Adrenal dysfunction is therefore a common upstream contributor to both MCAS and POTS.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

The MCAS-POTS overlap evaluation requires testing that spans autonomic, mast cell, inflammatory, and autoimmune domains. No single specialty typically orders this comprehensive panel.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient with POTS unresponsive to beta-blockers: Heart rate control achieved on metoprolol but symptoms of flushing, GI cramping, and brain fog persist. The tachycardia was controlled but the mast cell component driving vasodilation, GI dysfunction, and neuroinflammation was never identified. Adding H1/H2 antihistamines and cromolyn sodium produced the symptom improvement the beta-blocker alone could not achieve.
• The MCAS patient with unexplained exercise intolerance: Diagnosed with MCAS, taking antihistamines, but unable to exercise without severe lightheadedness and tachycardia. Active standing test confirmed concurrent POTS. Graduated recumbent exercise, salt and fluid loading, and compression garments addressed the autonomic component while mast cell stabilization continued.
• Post-COVID onset of both conditions simultaneously: A 34-year-old previously healthy woman developing tachycardia, flushing, food reactivity, brain fog, and GI symptoms 6 weeks after COVID infection. Autonomic testing confirmed POTS; mast cell mediators confirmed MCAS. Post-infectious immune dysregulation triggered both conditions simultaneously. Dual-system treatment with immune modulation, mast cell stabilization, and graduated reconditioning produced progressive improvement over 4 months.
• The hypermobile patient with the full triad: Beighton score 7/9, lifelong joint hypermobility. Developed POTS in adolescence, MCAS symptoms appearing in her twenties. The connective tissue disorder (hypermobile EDS) was the upstream structural predisposition for both conditions. Treatment required addressing all three components: POTS reconditioning, MCAS stabilization, and joint protection and physical therapy for the EDS.

Treatment and Optimization Strategy

Dual-System Approach

Effective treatment of MCAS-POTS overlap requires addressing both the mast cell and autonomic components simultaneously. Treating one in isolation produces partial results because the untreated condition continues to drive the treated one.

What Most Doctors Miss

• Only one condition is diagnosed: the most common error is diagnosing POTS without screening for MCAS, or diagnosing MCAS without evaluating autonomic function. The overlap is clinically significant and changes treatment strategy.
• Mast cell mediator testing is not performed correctly: plasma histamine requires chilled specimen handling, and 24-hour urine collections for N-methylhistamine and prostaglandin D2 metabolites require refrigeration throughout. Incorrect specimen handling produces false negatives.
• The EDS connection is not evaluated: the triad of MCAS, POTS, and hypermobile EDS is one of the best-characterized overlap syndromes in complex chronic illness, yet Beighton scoring and hypermobility assessment are rarely performed in either POTS or MCAS evaluations.
• Post-infectious onset is not recognized as a pattern: new-onset MCAS-POTS overlap after viral illness (particularly COVID-19) is increasingly prevalent, but the simultaneous onset of both conditions is frequently attributed to deconditioning or anxiety rather than immune-mediated dual-system dysfunction.

When to Seek Medical Care

If you have POTS with concurrent flushing, GI reactivity, urticaria, or medication sensitivities, or if you have MCAS with unexplained orthostatic intolerance, exercise intolerance, or positional tachycardia, evaluation for the overlap syndrome is warranted. This is especially important if your symptoms began after a viral illness, if you have joint hypermobility, or if treatment of one condition alone has produced inadequate results.

At The Lamkin Clinic, MCAS-POTS overlap evaluation includes active standing testing, mast cell mediator assessment, inflammatory and autoimmune markers, cortisol and adrenal evaluation, thyroid panel, and hypermobility screening, reviewed as an integrated multisystem profile.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches MCAS-POTS Overlap

At The Lamkin Clinic, MCAS-POTS overlap evaluation includes objective autonomic testing, mast cell mediator assessment, comprehensive inflammatory and autoimmune markers, cortisol and adrenal evaluation, and hypermobility screening. Treatment is built as a dual-system protocol: mast cell stabilization and autonomic reconditioning are implemented together, with anti-inflammatory and immune modulation addressing the shared upstream drivers.

Related Conditions

Related Symptoms